Possibility of milk utilization in hilly-mountainous region of Herzegovina

Autori opisuju proizvodnju mlijeka i mliječnih proizvoda na brdsko-planinskom području Hercegovine. Danas postoji na tom području samo jednu suvremena mljekara u Mostaru, dok se lokalno vrši prerada u različite kvalitetne mliječne proizvode, kao što su kajmak, vareni sir iz mješine, suhi sir, presukača, bijeli sir. Uz organizirani otkup mogla bi se još više razviti prerada u autohtone proizvode koji svojom kvalitetom mogu zadovoljiti suvremeno tržište.The authors describe production of milk and dairy products in the hilly-mountainous region of Herzegovina. Today there is only one modern dairy plant in Mostar, hut locally many dairy products are manufactured as kajmak dry cheese, presukača etc. With better organization of milk collecting, man products and better quality could be achieved for the market

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

<p>Abstract</p> <p>Background</p> <p>Diffusion of new drugs in the health care market affects patients' access to new treatment options and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs), diffused in the health care market in Taiwan.</p> <p>Methods</p> <p>Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan's National Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration (maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were estimated for analyses on the diffusion parameters.</p> <p>Results</p> <p>Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital's prior anti-diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50).</p> <p>Conclusions</p> <p>Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription volume of Anti-diabetic drugs.</p

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

<p>Abstract</p> <p>Background</p> <p>Diffusion of new drugs in the health care market affects patients' access to new treatment options and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs), diffused in the health care market in Taiwan.</p> <p>Methods</p> <p>Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan's National Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration (maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were estimated for analyses on the diffusion parameters.</p> <p>Results</p> <p>Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital's prior anti-diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50).</p> <p>Conclusions</p> <p>Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription volume of Anti-diabetic drugs.</p

Análise do impacto do progresso tecnológico nos custos do tratamento hospitalar: o caso do tratamento para litíase urinária no Hospital Universitário de Brasília

O progresso tecnológico na área de saúde tem provocado a elevação dos custos da assistência médica, preocupando a população mundial, os agentes privados e os responsáveis pelas políticas públicas. Estetrabalho apresenta uma análise do impacto do progresso tecnológico - delimitado, neste estudo, à incorporação de equipamentos médicos - nos custos do tratamento hospitalar. Para cumprir o objetivo, foram escolhidos ostratamentos médicos para litíase urinária - litotripsia e cirurgia - devido ao histórico de relevantes avanços tecnológicos. O estudo de caso foi realizado no Serviço de Litotripsia e no Centro Cirúrgico do Hospital Universitário de Brasília (HUB), no período de 2001 a 2003. Foram comparados os custos e as receitas diferenciais das alternativas de tratamento para calculose urinária em quatro opções de decisão. Para testar a robustez dos resultados, foi incorporada a variável incerteza, por meio de simulações no sistema Crystall Ball, realizando 50.000 iterações. Os principais impactos do progresso tecnológico nos custos do tratamento paralitíase urinária são: aumento da capacidade instalada, geração de despesa com obsolescência e aumento das receitas

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

International audienc

The reference site collaborative network of the european innovation partnership on active and healthy ageing

Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs